Benefytt (BFYT) 10-Q 30 Oct 18 2018 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2018	Oct. 25, 2018
Class of Stock [Line Items]
Entity Registrant Name	Health Insurance Innovations, Inc.
Entity Central Index Key	1,561,387
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Trading Symbol	HIIQ
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,018
Class A Common Stock
Class of Stock [Line Items]
Entity Common Stock, Shares Outstanding		14,405,824
Class B Common Stock
Class of Stock [Line Items]
Entity Common Stock, Shares Outstanding		2,541,667

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 33,135,000	$ 40,907,000
Restricted cash	15,140,000	14,920,000
Accounts receivable, net, prepaid expenses and other current assets	2,661,000	2,227,000
Advanced commissions, net	38,270,000	39,549,000
Income taxes receivable	2,542,000	0
Total current assets	91,748,000	97,603,000
Long-term advanced commissions	4,380,000	0
Property and equipment, net	5,400,000	5,408,000
Goodwill	41,076,000	41,076,000
Intangible assets, net	4,551,000	5,942,000
Deferred tax assets	26,160,000	14,960,000
Other assets	77,000	96,000
Total assets	173,392,000	165,085,000
Current liabilities:
Accounts payable and accrued expenses	37,741,000	39,725,000
Deferred revenue	221,000	662,000
Income taxes payable	0	787,000
Due to member	1,137,000	1,775,000
Other current liabilities	11,000	5,000
Total current liabilities	39,110,000	42,954,000
Due to member	26,293,000	15,096,000
Other liabilities	18,000	34,000
Total liabilities	65,421,000	58,084,000
Commitments and contingencies
Stockholders’ equity:
Preferred stock (par value $0.001 per share, 5,000,000 shares authorized; no shares issued and outstanding as of September 30, 2018 and December 31, 2017)	0	0
Additional paid-in capital	91,960,000	71,770,000
Treasury stock, at cost (890,621 and 380,777 shares as of September 30, 2018 and December 31, 2017, respectively)	(29,859,000)	(6,887,000)
Retained earnings	29,361,000	19,305,000
Total Health Insurance Innovations, Inc. stockholders’ equity	91,479,000	84,205,000
Noncontrolling interests	16,492,000	22,796,000
Total stockholders’ equity	107,971,000	107,001,000
Total liabilities and stockholders' equity	173,392,000	165,085,000
Class A Common Stock
Stockholders’ equity:
Common stock	14,000	13,000
Class B Common Stock
Stockholders’ equity:
Common stock	$ 3,000	$ 4,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2018	Dec. 31, 2017
Preferred stock, par value (in USD per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Treasury stock, shares (in shares)	890,621	380,777
Class A Common Stock
Common stock, par value (in USD per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	14,405,824	12,731,758
Common stock, shares outstanding (in shares)	13,515,203	12,350,981
Class B Common Stock
Common stock, par value (in USD per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	20,000,000	20,000,000
Common stock, shares issued (in shares)	2,541,667	3,841,667
Common stock, shares outstanding (in shares)	2,541,667	3,841,667

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income (unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Income Statement [Abstract]
Revenues (premium equivalents of $114,498 and $99,407 for the three months ended September 30, 2018 and 2017, respectively and $330,633 and $289,243 for the nine months ended September 30, 2018 and 2017, respectively)	$ 74,013	$ 63,335	$ 213,487	$ 180,986
Operating expenses:
Third-party commissions	46,695	36,603	131,792	103,146
Credit card and ACH fees	1,570	1,289	4,318	3,704
Selling, general and administrative	18,260	15,503	54,197	45,457
Depreciation and amortization	1,270	1,028	3,655	2,958
Total operating expenses	67,795	54,423	193,962	155,265
Income from operations	6,218	8,912	19,525	25,721
Other (income) expense:
Interest (income) expense	15	(2)	(39)	(2)
TRA expense	721	0	721	0
Other expense	29	23	88	27
Net income before income taxes	5,453	8,891	18,755	25,696
Provision for income taxes	1,466	2,889	4,757	4,220
Net income	3,987	6,002	13,998	21,476
Net income attributable to noncontrolling interests	943	2,117	3,942	7,374
Net income attributable to Health Insurance Innovations, Inc.	$ 3,044	$ 3,885	$ 10,056	$ 14,102
Net income per share attributable to Health Insurance Innovations, Inc.
Basic (in USD per share)	$ 0.24	$ 0.33	$ 0.83	$ 1.31
Diluted (in USD per share)	$ 0.22	$ 0.30	$ 0.76	$ 1.21
Weighted average Class A common shares outstanding
Basic (in shares)	12,853,739	11,700,941	12,130,722	10,724,750
Diluted (in shares)	14,060,453	12,742,952	13,302,811	11,692,755

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Income (unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Income Statement [Abstract]
Premium equivalent amount	$ 114,498	$ 99,407	$ 330,633	$ 289,243

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (unaudited) - USD ($) $ in Thousands	Total	Additional Paid-in Capital	Treasury Stock	Retained Earnings	Noncontrolling Interests	Class A Common Stock	Class A Common StockCommon Stock	Class B Common StockCommon Stock
Beginning balance (in shares) at Dec. 31, 2016			(119,544)				8,036,705	6,841,667
Beginning balance at Dec. 31, 2016	$ 80,078	$ 47,849	$ (1,122)	$ 1,420	$ 31,916		$ 8	$ 7
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	26,491			17,885	8,606
Issuance of Class A common stock in private offering (in shares)							3,000,000
Issuance of Class A common stock in private offering	16,487	16,484					$ 3
Exchange of Series B Membership interest and exchange and cancellation of Class B common stock (in shares)								(3,000,000)
Exchange of Series B Membership interest and exchange and cancellation of Class B common stock	(14,374)				(14,371)			$ (3)
Repurchases of Class A common stock (in shares)			222,184			(222,184)	(222,184)
Repurchases of Class A common stock	(4,923)		$ (4,923)
Issuance of Class A common stock under equity compensation plans (in shares)							1,575,509
Issuance of Class A common stock under equity compensation plans	33	31					$ 2
Class A common stock withheld in Treasury from restricted share vesting (in shares)			39,049				(39,049)
Class A common stock withheld in Treasury from restricted share vesting	(842)		$ (842)
Stock-based compensation	7,404	7,404
Contributions (distributions)	(3,353)	2			(3,355)
Ending balance (in shares) at Dec. 31, 2017			(380,777)				12,350,981	3,841,667
Ending balance at Dec. 31, 2017	107,001	71,770	$ (6,887)	19,305	22,796		$ 13	$ 4
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	13,998			10,056	3,942
Issuance of Class A common stock in private offering (in shares)							1,300,000
Issuance of Class A common stock in private offering	9,232	9,231					$ 1
Exchange of Series B Membership interest and exchange and cancellation of Class B common stock (in shares)								(1,300,000)
Exchange of Series B Membership interest and exchange and cancellation of Class B common stock	(8,048)				(8,047)			$ (1)
Repurchases of Class A common stock (in shares)			426,135			(426,135)	(426,135)
Repurchases of Class A common stock	(19,502)		$ (19,502)
Issuance of Class A common stock under equity compensation plans (in shares)							374,066
Issuance of Class A common stock under equity compensation plans	$ 6	6
Class A common stock withheld in Treasury from restricted share vesting (in shares)	(83,700)		83,709				(83,709)
Class A common stock withheld in Treasury from restricted share vesting	$ (3,470)		$ (3,470)
Stock-based compensation	10,936	10,936
Contributions (distributions)	(2,182)	17			(2,199)
Ending balance (in shares) at Sep. 30, 2018			(890,621)				13,515,203	2,541,667
Ending balance at Sep. 30, 2018	$ 107,971	$ 91,960	$ (29,859)	$ 29,361	$ 16,492		$ 14	$ 3

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Operating activities:
Net income	$ 3,987,000	$ 6,002,000	$ 13,998,000	$ 21,476,000	$ 26,491,000
Adjustments to reconcile net income to net cash provided by operating activities:
Stock-based compensation			10,503,000	4,437,000
Depreciation and amortization	1,270,000	1,028,000	3,655,000	2,958,000
Loss on disposal of assets			1,000	0
Deferred income taxes			460,000	1,079,000
Changes in operating assets and liabilities:
(Increase) decrease in accounts receivable, prepaid expenses and other assets			(398,000)	96,000
(Increase) decrease in advanced commissions			(3,101,000)	9,991,000
Increase in income taxes receivable			(2,542,000)	0
Decrease in income taxes payable			(787,000)	(935,000)
(Decrease) increase in accounts payable, accrued expenses and other liabilities			(1,994,000)	1,682,000
Decrease in deferred revenue			(441,000)	(173,000)
Increase in due to member pursuant to tax receivable agreement			721,000	0
Net cash provided by operating activities			20,075,000	40,611,000
Investing activities:
Capitalized internal-use software			(1,290,000)	(2,104,000)
Purchases of property and equipment			(534,000)	(239,000)
Net cash used in investing activities			(1,824,000)	(2,343,000)
Financing activities:
Payments for noncompete obligation			0	(96,000)
Payments related to tax withholding for share-based compensation	(2,200,000)	(263,000)	(3,470,000)	(448,000)
Issuances of Class A common stock under equity compensation plans			6,000	32,000
Purchases of Class A common stock pursuant to share repurchase plan			(19,502,000)	0
Distributions to member			(2,837,000)	(5,318,000)
Net cash used in financing activities			(25,803,000)	(5,830,000)
Net (decrease) increase in cash and cash equivalents, and restricted cash			(7,552,000)	32,438,000
Cash and cash equivalents, and restricted cash at beginning of period			55,827,000	25,370,000	25,370,000
Cash and cash equivalents, and restricted cash at end of period	48,275,000	57,808,000	48,275,000	57,808,000	$ 55,827,000
Supplemental cash flow information:
Income taxes, net			7,651,000	4,113,000
Interest			6,000	10,000
Non-cash investing activities:
Capitalized stock-based compensation	$ 89,000	$ 0	433,000	0
Loss on disposal of assets			1,000	0
Non-cash financing activities:
Change in due to member related to Exchange Agreement			10,476,000	18,619,000
Change in deferred tax asset related to Exchange Agreement			(11,661,000)	(20,732,000)
Issuance of Class A common stock in a private offering related to Exchange Agreement			9,232,000	16,487,000
Exchange of Class B membership interests related to Exchange Agreement			$ (8,048,000)	$ (14,374,000)

Organization, Basis of Presenta

Organization, Basis of Presentation and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Basis of Presentation and Summary of Significant Accounting Policies	Organization, Basis of Presentation and Summary of Significant Accounting Policies Health Insurance Innovations, Inc. is a Delaware corporation incorporated on October 26, 2012. In this quarterly report, unless the context suggests otherwise, references to the “Company,” “we,” “us,” and “our” refer (1) prior to the February 13, 2013 closing of an initial public offering (“IPO”) of the Class A common stock of Health Insurance Innovations, Inc., to Health Plan Intermediaries, LLC (“HPI”) and Health Plan Intermediaries Sub, LLC (“HPIS”), its consolidated subsidiary, and (2) after the IPO, to Health Insurance Innovations, Inc. and its consolidated subsidiaries. The terms “HIIQ” and “HPIH” refer to the stand-alone entities Health Insurance Innovations, Inc., and Health Plan Intermediaries Holdings, LLC, respectively. The terms “HealthPocket” or “HP” refer to HealthPocket, Inc., our wholly owned subsidiary which was acquired by HPIH on July 14, 2014. The term “ASIA” refers to American Service Insurance Agency LLC, a wholly owned subsidiary which was acquired by HPIH on August 8, 2014. HP, and ASIA are consolidated subsidiaries of HPIH, which is a consolidated subsidiary of HIIQ. Principles of Consolidation and Basis of Presentation The accompanying condensed consolidated financial statements for the three and nine months ended September 30, 2018 and 2017 have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information. Accordingly, they do not include all of the financial information and footnotes required by GAAP for complete financial statements. The information included in this quarterly report, including the interim condensed consolidated financial statements and the accompanying notes, should be read in conjunction with the audited consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 . In the opinion of management, the accompanying condensed consolidated financial statements reflect all adjustments, which, except as disclosed in the below section titled "Reclassifications," include only normal recurring adjustments, necessary to state fairly the financial position, results of operations, stockholders' equity, and cash flows of the Company. The condensed consolidated results for th e three and nine months ended September 30, 2018 are not necessarily indicative of the results to be expected for any subsequent interim period or for the year ending December 31, 2018 . As an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), we benefit from certain temporary exemptions from various reporting requirements, including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We have also elected under the JOBS Act to delay the adoption of new and revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. As a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates. These exemptions will apply for a period of five years following the completion of our IPO on February 13, 2013. The Company will cease to be an emerging growth company as of December 31, 2018 . Summary of Significant Accounting Policies The following is an update to our significant accounting policies described in Note 1, Organization, Basis of Presentation, and Summary of Significant Accounting Policies, in our audited consolidated financial statements for the year ended December 31, 2017 included in our Annual Report on Form 10-K. Reclassifications The Company reclassified in-transit credit card and ACH receipts, during the first quarter of 2018, previously included in accounts receivable, net, prepaid expenses, and other current assets on the balance sheet to cash and cash equivalents. The reclassification resulted in a $1.6 million increase in cash and cash equivalents and a corresponding decrease in accounts receivable, net, prepaid expense and other current assets as of December 31, 2017 and a decrease of $217,000 in operating cash flows on the condensed consolidated statement of cash flows for the nine months ended September 30, 2017 . The changes described do not affect the condensed consolidated statements of income or stockholders’ equity. Use of Estimates The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities at the date of the condensed consolidated financial statements. These estimates also affect the reported amounts of revenues and expenses during the reporting periods. Actual results could materially differ from those estimates. Recent Accounting Pronouncements In the following summary of recent accounting pronouncements, all references to effective dates of Financial Accounting Standards Board (“FASB”) guidance relate to nonpublic entities unless otherwise noted. As noted above, we have elected to delay the adoption of new and revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies under the provisions of the JOBS Act. Recently adopted accounting pronouncements In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, an update which requires companies to include amounts generally described as restricted cash and restricted cash equivalents in cash and cash equivalents when reconciling beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company has adopted this update during the first quarter of 2018 and has properly reported restricted cash and restricted cash equivalents in our beginning-of-period and end-of-period total cash and cash equivalents balance. Accounting pronouncements not yet adopted In July 2018, the FASB issued ASU No. 2018-10, Codification Improvements to Topic 842, Leases, to add clarity to certain areas within ASU 2016-02. The effective date and transition requirements will be the same as ASU 2016-02. The Company will evaluate and adopt this ASU in conjunction with ASU 2016-02. In May 2017, the FASB issued Accounting Standards Update (“ASU”) No. 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting, which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. The amendments are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted. We are currently evaluating the impact of adopting this standard, and will adopt this guidance on December 31, 2018, the date our emerging growth company status expires. We do not expect it to have a significant impact on our consolidated financial statements and disclosures. We will adopt this standard prospectively as required by the standard. In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment, which eliminates the requirement to calculate the implied fair value of goodwill (i.e., Step 2 of the goodwill impairment test) to measure a goodwill impairment charge. Instead, entities will record an impairment charge based on the excess of a reporting unit’s carrying amount over its fair value. This guidance will be effective for interim or annual goodwill impairment tests in fiscal years beginning after December 15, 2019 and will be applied prospectively. Early adoption is permitted for any impairment tests performed after January 1, 2017. The Company does not believe that this guidance will have a material impact on our consolidated financial statements. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, which provides amendments to the codification for eight specific cash flow issues such as the classification of debt prepayment or debt extinguishment costs to the classification of the proceeds from the settlement of insurance claims. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2018, and interim periods within fiscal years beginning after December 15, 2019. Early adoption is permitted, including adoption in an interim period. The Company will adopt this guidance on December 31, 2018, the date our emerging growth company status expires. The standard will be implemented using a retrospective transition method to each period presented, except where it is impracticable, and the amendments for those issues will be applied prospectively. We are currently evaluating the impact of this guidance on our consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which modifies lease accounting for lessees to increase transparency and comparability by requiring organizations to recognize lease assets and lease liabilities on the balance sheet and increasing disclosures about key leasing arrangements. The amendment updates the critical determinant from capital versus operating to whether a contract is or contains a lease because lessees are required to recognize lease assets and lease liabilities for all leases - financing and operating - other than short term. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. We will adopt this guidance in reporting periods beginning after December 15, 2018. The adoption of this standard will impact the Company’s consolidated balance sheet, but the Company is still assessing any other impacts this standard will have on its consolidated financial statements. The Company does not believe that the impact of adopting this standard will be material to the consolidated financial statements. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) which amends the existing revenue recognition standards. The standard is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, new and enhanced disclosures will be required. For most public entities, the standard became effective for annual and interim reporting periods beginning after December 15, 2017. For all other entities, the amendments in this update are effective for reporting periods beginning after December 15, 2018. As an emerging growth company, we are required to adopt this guidance on December 31, 2018, the date our emerging growth company status expires. We will apply the new standard using a modified retrospective approach with the cumulative effect of its application recognized at the date of initial application. We are implementing this new standard in close consultation with our Audit Committee. We have identified our various revenue streams that could be impacted by the new standard and have reviewed individual customer contracts related to these revenue streams to determine material differences between the current and new revenue standards. The new standard will impact the majority of our revenue streams. In accordance with ASU 2014-09, we will make estimates, including, but not limited to, the estimated revenue to be paid to us over the estimated life of the member policy. Our adoption of ASU 2014-09 will significantly change the timing of our revenue recognition over the course of the year, depending on when applications are approved. We have identified that we generally have two performance obligations, as defined in the standard, to our customers. These performance obligations typically include: 1. Sales and Enrollment 2. Bill, Collect, and Support Under current revenue recognition guidance, we generally recognize revenue ratably over the policy period as the members remit their payments. Under the new standard, the Sales and Enrollment performance obligation is considered complete once an application is approved. At the time of approval, we would record the entire amount of revenue allocated to the Sales and Enrollment performance obligation that the Company expects to receive over the life of the insurance policy or discount benefit plan. This estimate will be based on the expected persistency of the underlying insurance policy or discount benefit plan. The remaining performance obligations will be recognized ratably over the estimated life of the insurance policy or discount benefit plan. The Company has not concluded on the treatment of its cost to fulfill and obtain contracts under the new standard. We anticipate the adoption of the new standard will have a material impact to our opening balance sheet as of January 1, 2018 due to the cumulative effect of adopting the new standard. In addition, we believe our adoption of the new standard will have a material impact on our consolidated balance sheet and consolidated statement of income for the year ended December 31, 2018 however, a reasonable estimate of the quantitative impact of adopting this standard cannot be made at this time. To prepare for the additional disclosure requirements, we are currently implementing additional tools to support our revenue recognition and data collection processes, which will be in place and effective on December 31, 2018. The Company has reviewed all other issued, but not yet effective, accounting pronouncements and does not believe the future adoption of any such pronouncements may be expected to cause a material impact on our financial statements.

Long-term Advanced Commissions

Long-term Advanced Commissions	9 Months Ended
	Sep. 30, 2018
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Long-term Advanced Commissions	Long-term Advanced Commissions Long-term advanced commissions as of September 30, 2018 were $4.4 million . There were no long-term advanced commissions as of December 31, 2017 . The Company has made no allowance for uncollectible accounts.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	9 Months Ended
	Sep. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets There have been no material changes to Goodwill and Intangible assets from amounts reported in the Company’s Annual Report on Form 10-K at December 31, 2017 except for amortization expense recorded for definite lived intangible assets. Amortization expense for the three and nine months ended September 30, 2018 was $464,000 and $1.4 million , respectively, compared to $479,000 and $1.5 million for the three and nine months ended September 30, 2017 , respectively.

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	9 Months Ended
	Sep. 30, 2018
Payables and Accruals [Abstract]
Accounts Payable and Accrued Expenses	Accounts Payable and Accrued Expenses Accounts payable and accrued expenses consisted of the following as of ($ in thousands): September 30, 2018 December 31, 2017 Carriers and vendors payable $ 15,412 $ 14,726 Commissions payable 10,157 8,811 Accrued compensation and benefits 6,549 7,116 Accrued refunds 1,107 1,940 Accounts payable 323 3,725 Accrued professional fees 1,315 820 Accrued credit card/ACH fees 488 483 Other accrued expenses 2,390 2,104 Total accounts payable and accrued expenses $ 37,741 $ 39,725 As of September 30, 2018 , included in accrued compensation and benefits is $3.3 million related to severance from the termination of the Company's founder, Mr. Kosloske, HP executives, Messrs. Telkamp and Wang, and other Company employees.

Debt

Debt	9 Months Ended
	Sep. 30, 2018
Debt Disclosure [Abstract]
Debt	Debt There have been no changes to Company debt from amounts reported in the Company’s Annual Report on Form 10-K as of December 31, 2017. As of September 30, 2018 , we had no outstanding balance from draws on the Credit Facility and $30.0 million was available to be drawn upon. The Company is in compliance with all debt covenants.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2018
Equity [Abstract]
Stockholders' Equity	Stockholders’ Equity Except for the items detailed below, there have been no material changes to Stockholders' Equity as reported in the Company’s Annual Report on Form 10-K at December 31, 2017: Tax Obligation Settlements and Treasury Stock Transactions Treasury stock is recorded pursuant to the surrender of shares by certain employees to satisfy statutory tax withholding obligations on vested restricted stock awards. In addition, certain forfeited stock-based awards are transferred to and recorded as treasury stock, and certain restricted stock awards may have been granted from shares in Treasury. During the three and nine months ended September 30, 2018 , there were 45,400 and 83,700 shares, respectively, transferred to Treasury for statutory tax withholding obligations as a result of vested restricted stock awards. During the three and nine months ended September 30, 2017 , there were 10,300 and 21,900 shares, respectively, transferred to Treasury for statutory tax withholding obligations as a result of vested restricted stock awards. During the three and nine months ended September 30, 2018 and 2017 , there were no shares transferred to Treasury as a result of forfeitures of restricted stock awards. For the three and nine months ended September 30, 2018 , there were cash outflows of $2.2 million and $3.5 million , respectively, with respect to shares redeemed to cover the tax obligations for the settlement of vested restricted stock. During the three and nine months ended September 30, 2017 , there was $263,000 and $448,000 , respectively, of cash outflows with respect to shares redeemed to cover the tax obligations for the settlement of vested restricted stock. The increase in 2018 was due to the accelerated vesting of restricted stock from the termination of the HP executives, Sheldon Wang and Bruce Telkamp, during the three months ended September 30, 2018 . Share Repurchase Program On October 13, 2017, the Company’s Board of Directors authorized a share repurchase program for up to $50.0 million of the Company’s outstanding Class A Common Stock. During the three and nine months ended September 30, 2018 we repurchased 310,890 and 426,135 shares, respectively, of our registered Class A common stock under the current share repurchase program at an average price per share of $50.50 and $45.77 , respectively. During the year ended December 31, 2017 , we repurchased 222,184 shares of our registered Class A common stock under the current share repurchase program at an average price per share of $22.15 . During the three and nine months ended September 30, 2017 there were no repurchases made under the previous share repurchase program. Exchange Agreement Under the Exchange Agreement, dated February 13, 2013, between the Company and HPI and HPIS (the “Exchange Agreement”), on June 6, 2018, HPI exchanged 1,287,000 shares of Class B common stock of HIIQ and 1,287,000 membership interests of HPIH for 1,287,000 shares of Class A common stock of HIIQ. On that same date, HPIS exchanged 13,000 shares of Class B common stock of HIIQ and 13,000 membership interests of HPIH for 13,000 shares of Class A common stock of HIIQ. Following those exchanges, on June 7, 2018, HPI and HPIS initiated a sale for 1,287,000 and 13,000 shares, respectively, of HIIQ's Class A Common stock and sold such shares of Class A common stock in a transaction under Rule 144 for a price of $31.01 per share, with the sale settling on June 11, 2018. See Note 10 for further information on the Exchange Agreement.

Stock-based Compensation

Stock-based Compensation	9 Months Ended
	Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based Compensation	Stock-based Compensation For stock appreciation rights ("SARs") granted or modified during the nine months ended September 30, 2018 and 2017 , the Black-Scholes option-pricing model was used with the following weighted average assumptions: Nine Months Ended September 30, 2018 2017 Risk-free rate 2.3 % 1.7 % Expected life 0.3 years 4.8 years Expected volatility 44.6 % 64.0 % Expected dividend none none The following table summarizes restricted shares and SARs granted during the three and nine months ended September 30, 2018 and 2017 (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Restricted shares 50 — 63 855 SARs — 100 — 185 The following table summarizes stock-based compensation expense for the three and nine months ended September 30, 2018 and 2017 ($ in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Restricted shares $ 4,165 $ 2,246 $ 8,940 $ 3,306 SARs 268 434 1,996 1,116 Stock options — 3 — 15 Less amounts capitalized for internal-use software (89 ) — (433 ) — Total $ 4,344 $ 2,683 $ 10,503 $ 4,437 The following table summarizes unrecognized stock-based compensation expense and the remaining weighted average period over which such stock-based compensation expense is expected to be recognized as of September 30, 2018 ($ in thousands): Unrecognized Expense Weighted Average Remaining Years Restricted shares $ 9,062 1.8 SARs 1,234 1.9 Total $ 10,296 The amounts in the table above do not include the cost of any additional awards that may be granted in future periods nor any changes in our forfeiture rate. During the three and nine months ended September 30, 2018 , there were 143,100 and 163,000 SARs exercised, respectively, resulting in an increase of 111,200 and 125,900 issued shares of Class A common stock, respectively. During the three and nine months ended September 30, 2017 there were 110,500 and 1,400,000 SARs exercised, respectively, resulting in an increase of 89,800 and 1,000,000 shares of issued Class A common stock, respectively. During the three and nine months ended September 30, 2018 there were 7,500 SARs forfeited. During the three and nine months ended September 30, 2017 , there were 17,500 outstanding SARs forfeited. During the three and nine months ended September 30, 2018 , there were 2,500 and 5,800 options exercised, respectively. During the three and nine months ended September 30, 2017 there were 10,700 and 29,500 options exercised, respectively. During the three and nine months ended September 30, 2018 and 2017 there were no options forfeited. During the three months ended September 30, 2018 , there were no restricted stock awards issued for performance shares. During the nine months ended September 30, 2018 , there were 179,400 restricted stock awards issued for performance shares. These awards were previously granted in which the performance metrics were contractually satisfied during the period. No restricted stock awards were issued for performance shares in the three and nine months ended September 30, 2017 . During the three and nine months ended September 30, 2018 , there were 35,000 performance shares forfeited. During the three and nine months ended September 30, 2017 , there were no performance shares forfeited. We recognized income tax benefits from stock-based activity of $402,000 and $760,000 for the three and nine months ended September 30, 2018 , respectively. We recognized income tax benefits from stock-based activity of $380,000 and $4.0 million , for the three and nine months ended September 30, 2017 . For the three and nine months ended September 30, 2018 , we capitalized $89,000 and $433,000 , respectively, of stock-based compensation expense related to the development of internal-use software. No stock-based compensation expense was capitalized during the three and nine months ended September 30, 2017 . See Note 1 and Note 3 of our Annual Report on Form 10-K for the period ended December 31, 2017 for further information on our internal-use software.

Net Income Per Share

Net Income Per Share	9 Months Ended
	Sep. 30, 2018
Earnings Per Share [Abstract]
Net Income Per Share	Net Income per Share The computations of basic and diluted net income per share attributable to HIIQ for the three and nine months ended September 30, 2018 and 2017 were as follows ($ in thousands, except share and per share data): Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Basic net income attributable to Health Insurance Innovations, Inc. $ 3,044 $ 3,885 $ 10,056 $ 14,102 Weighted average shares—basic 12,853,739 11,700,941 12,130,722 10,724,750 Effect of dilutive securities: Restricted shares 573,047 466,581 597,012 258,218 SARs 629,038 561,788 568,692 685,583 Stock options 4,629 13,642 6,385 24,204 Weighted average shares—diluted 14,060,453 12,742,952 13,302,811 11,692,755 Basic net income per share attributable to Health Insurance Innovations, Inc. $ 0.24 $ 0.33 $ 0.83 $ 1.31 Diluted net income per share attributable to Health Insurance Innovations, Inc. $ 0.22 $ 0.30 $ 0.76 $ 1.21 Potential common shares are included in the diluted per share calculation when dilutive. Potential common shares consist of Class A common stock issuable through unvested restricted stock grants and stock appreciation rights and are calculated using the treasury stock method. The following securities were not included in the calculation of diluted net income per share because such inclusion would be antidilutive (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Restricted Shares 50 — 50 405 SARs — 16 105 — Additionally, potential common stock totaling 2,541,667 shares at September 30, 2018 and 3,841,667 shares at September 30, 2017 issuable under the exchange agreement were not included in diluted shares because such inclusion would be antidilutive. See Note 7 in our Annual Report on Form 10-K for the year ended December 31, 2017 for further details on the exchange agreement.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes HPIH is taxed as a partnership for income tax purposes; as a result, it is not subject to entity-level federal or state income taxation, but its members are liable for taxes with respect to their allocable shares of each company’s respective net taxable income. We are subject to U.S. corporate federal, state, and local income taxes on our allocable share of net taxable income that is reflected in our condensed consolidated financial statements. The effective tax rate for the three and nine months ended September 30, 2018 was 26.9% and 25.4% , respectively. The effective tax rate for the three and nine months ended September 30, 2017 was 32.5% and 16.4% , respectively. For the three and nine months ended September 30, 2018 the provision for income taxes was $1.5 million and $4.8 million , respectively. For the three and nine months ended September 30, 2017 , the provision for income taxes was $2.9 million and $4.2 million , respectively. Deferred taxes on our investment in HPIH are measured on the difference between the carrying amount of our investment in HPIH and the corresponding tax basis of this investment. We do not measure deferred taxes on differences within HPIH, as those differences inherently comprise our deferred taxes on our external investment in HPIH. Due to the ownership structure of HP, which is a taxable entity, it cannot join in a consolidated tax filing with HIIQ. Consequently, its federal and state tax jurisdictions are separate from those of HIIQ, which prevents deferred tax assets and liabilities of HIIQ and HP from offsetting one another. On a standalone basis, the effective tax rate for the three and nine months ended September 30, 2018 for HIIQ was 15.5% and 19.3% , respectively, while the effective tax rate for each of the three and nine months ended September 30, 2018 for HP was 0.0% . On a standalone basis, the effective tax rate for the three and nine months ended September 30, 2017 for HIIQ was 29.1% and 15% , respectively, while the effective tax rate for each of the three and nine months ended September 30, 2017 for HP was 3.7% . We account for uncertainty in income taxes using a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon audit, including resolution of related appeals or litigation processes, if any. The second step requires us to estimate and measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. Such amounts are subjective, as a determination must be made on the probability of various possible outcomes. We reevaluate uncertain tax positions on a quarterly basis. This evaluation is based on factors including, but not limited to, changes in facts or circumstances, changes in tax law, effectively settled issues under audit and new audit activity. Such a change in recognition and measurement could result in recognition of a tax benefit or an additional tax provision. For the three and nine months ended September 30, 2018 and 2017 , respectively, we did no t have a balance of gross unrecognized tax benefits, and as such, no amount would favorably affect the effective income tax rate in any future periods. The Company accounts for interest and penalties associated with uncertain tax positions as a component of tax expense, and none were included in the Company’s financial statements as there are no uncertain tax positions outstanding as of September 30, 2018 and 2017 , respectively. The Company’s 2014 through 2017 tax years remain subject to examination by tax authorities.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Health Plan Intermediaries, LLC HPI and its subsidiary HPIS, which are beneficially owned by Mr. Kosloske, a director and former executive officer of the Company, are deemed to be related parties of the Company by virtue of their Series B Membership Interests in HPIH, of which we are the managing member. During the nine months ended September 30, 2018 , HPIH paid cash distributions of $2.8 million for these entities related to estimated federal and state income taxes, pursuant to the operating agreement entered into by HPIH and HPI. Of these cash distributions, $638,000 was related to amounts accrued for at December 31, 2017 and included in Due to member account on the condensed consolidated balance sheet. For the nine months ended September 30, 2017 , $5.3 million in cash distributions were made for estimated federal and state income taxes. Pursuant to the operating agreement of HPIH, we determine when distributions will be made to the members of HPIH and the amount of any such distributions, except that HPIH is required by the operating agreement to make certain pro rata distributions to each member of HPIH quarterly on the basis of the assumed tax liabilities of the members. As of September 30, 2018 , no estimated federal or state income taxes were due. Tax Receivable Agreement On February 13, 2013, we entered into a Tax Receivable Agreement (the "TRA") with HPI and HPIS, as the holders of the HPIH Series B Membership Interests. The TRA requires us to pay to such holders 85% of the cash savings, if any, in U.S. federal, state, and local income tax we realize (or are deemed to realize in the case of an early termination payment, a change in control or a material breach by us of our obligations under the TRA) as a result of any possible future increases in tax basis and of certain other tax benefits related to entering into the TRA, including tax benefits attributable to payments under the TRA itself. This is the Company's obligation and not an obligation of HPIH, and the Company will benefit from the remaining 15% of any realized cash savings. For purposes of the TRA, cash savings in income tax is computed by comparing our actual income tax liability with our hypothetical liability had we not been able to utilize the tax benefits subject to the TRA itself. The TRA became effective upon completion of the IPO and will remain in effect until all such tax benefits have been used or expired, unless the Company exercises its right to terminate the TRA for an amount based on the agreed payments remaining to be made under the agreement or the Company breaches any of its material obligations under the TRA in which case all obligations will generally be accelerated and due as if the Company had exercised its right to terminate the agreement. Any potential future payments will be calculated using the market value of our Class A common stock at the time of the relevant exchange and prevailing tax rates in future years and will be dependent on us generating sufficient future taxable income to realize the benefit. Payments are generally due under the TRA within a specified period of time following the filing of our tax return for the taxable year with respect to which payment of the obligation arises. Exchanges of Series B Membership Interests, together with an equal number of shares of our Class B common stock, for shares of our Class A common stock, are expected to increase our tax basis in our share of HPIH’s tangible and intangible assets. These increases in tax basis are expected to increase our depreciation and amortization deductions and create other tax benefits and therefore may reduce the amount of tax that we would otherwise be required to pay in the future. As of September 30, 2018 , Series B Membership Interests, together with an equal number of shares of Class B common stock have been exchanged for a total of 6,125,000 shares of Class A common stock subsequent to the IPO. As of September 30, 2018 , as a result of these exchanges, we have recorded a liability of $27.4 million pursuant to the TRA, of which $1.1 million is included in current liabilities and $26.3 million is included in long-term liabilities on the accompanying condensed consolidated balance sheets. We have determined that this amount is probable of being paid based on our estimates of future taxable income. This liability represents the share of tax benefits payable to the entities beneficially owned by Mr. Kosloske, if we generate sufficient taxable income in the future. As of September 30, 2018 , we have made $1.2 million of cumulative payments under the TRA. Legal Proceedings The Company is subject to legal proceedings, claims, and liabilities that arise in the ordinary course of business. The Company accrues losses associated with legal claims when such losses are probable and reasonably estimable. If the Company determines that a loss is probable and cannot estimate a specific amount for that loss, but can estimate a range of loss, the best estimate within the range is accrued. If no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. Estimates are adjusted as additional information becomes available or circumstances change. Legal defense costs associated with loss contingencies are expensed in the period incurred. In addition to ordinary-course litigation that the Company does not believe to be material, the Company is a party to the proceedings and matters described below: State Regulatory Examinations Indiana Multistate Market Conduct Examination The Company is the subject of a previously disclosed multistate market conduct examination ("MCE") that commenced in April 2016 by the Market Actions Working Group of the National Association of Insurance Commissioners. The MCE, which is led by the Indiana Department of Insurance and is comprised of 43 participating state insurance departments, was initially focused on a review of HCC Life Insurance Company’s sales, marketing, and compliance practices relating to short-term medical plans. The MCE was later expanded to include the Company’s marketing, sales, compliance, and administration activities. During the period from May 2016 through June 2018, the Company was served with requests for information in the form of subpoenas, and the Company responded to the requests and has otherwise been fully cooperating with the examiners, including regular discussions to bring the examination to resolution. The California Department of Insurance published a December 2017 Regulatory Settlement Agreement between HCC and certain states participating in the HCC MCE (and other states have since published the same document); as the Company was not included in that reported settlement, the Company cannot predict whether the reported HCC settlement will affect the resolution or outcome of the examination of the Company. On October 3, 2018 the Company met with the MCE examiners for confidential settlement discussions. These discussions included updated feedback on the results of the examination, and discussion aimed toward potential resolution of the examination. The Company has made what it believes to be an appropriate accrual based on the nature and stage of current discussions with the MCE examiners but the Company is not able to reasonably estimate any additional settlement amount or range of settlement amounts. Under the rules of the MCE, the negotiations remain confidential. In addition to the MCE, we are aware that other states, including South Dakota are reviewing the sales practices and potential unlicensed sale of insurance by independently owned and operated third-party licensed-agent call centers utilized by the Company, although to the Company’s knowledge, none of these reviews are being conducted directly against the Company or call centers owned by the Company. Other states, including California and Missouri, have requested information of the Company relating to its sales practices, marketing, and other matters. Massachusetts Regulatory Action The Company received notification of a civil investigative demand from the Massachusetts Attorney General’s Office (“MAG”) on June 16, 2016. The MAG has requested certain information and documents from the Company which will be used to review the Company’s sales and marketing practices to ensure the Company is in compliance with Massachusetts laws and regulations. Additionally, the Company’s materials and sales and marketing practices are being evaluated in order to ensure that they are neither deceptive nor do they constitute unfair trade practices. The Company continues to cooperate with the MAG in the interest of bringing the matter to an agreeable conclusion. While the MAG has indicated it is amenable to exploring all available options, it is still too early to assess whether the MAG’s investigation will result in a material impact on the Company. The Company believes that based on the nature of the allegations raised by the MAG, a loss arising from the future assessment of a civil penalty against the Company is probable. Notwithstanding, due to the procedural stage of the investigative process, the settlement of another party (a carrier) for the same set of allegations, and the fact that the Company has neither requested nor received evidentiary material from the MAG, the Company is currently unable to estimate the amount of any potential civil penalty or determine a range of potential loss under the MAG’s investigation of the Company. It is possible there may be no financial loss, a nominal or minimal loss, or some other mutually satisfactory resolution reached with the MAG in connection with the MAG’s investigation of the Company. As of June 30, 2018, there have been no findings of any sort (including findings of breaches or wrongdoing) communicated to the Company by the MAG. Florida Regulatory Action On June 11, 2018, the Company received notice that the Florida Office of Insurance Regulation (“OIR”) had conducted an investigation as a result of allegations that the Company’s subsidiary, HealthPocket, Inc. d/b/a AgileHealthInsurance, had advertised inducements in the solicitation of insurance products via an independently owned, third-party website and made allegedly material misstatements on an insurance agency application for licensure. The Company has reviewed the allegations and supporting documents and disagrees with the allegations. The OIR has proposed a settlement stipulation for consent order to resolve the matter. If the Company does not proceed with the settlement stipulation, the OIR has stated it will recommend formal administrative proceedings. The Company currently anticipates that it will be able to resolve the matter amicably with the OIR. California Regulatory Action On August 29, 2018, the Company received an Order to Show Cause and Notice of Hearing from the California Department of Insurance alleging that the Company made misleading statements relating to health insurance policies. The Company is actively engaged with the Department to resolve the matter. We are proactively communicating and cooperating with all regulatory agencies involved in the above-described examinations and actions, and we continue to develop and enhance our compliance and control mechanisms. However, it is too early to determine whether any of these regulatory matters will have a material impact on our business. Any adverse finding could result in significant penalties or other liabilities and/or a requirement to modify our marketing or business practices and the practices of our third-party independent distributors, which could harm our business, results of operations, or financial condition. Moreover, an adverse regulatory action in one jurisdiction could result in penalties and adversely affect our license status or reputation in other jurisdictions due to the requirement that adverse regulatory actions in one jurisdiction be reported to other jurisdictions. Claims that involve independently licensed third-party insurance agencies and their agents, and independent insurance carriers, in which the Company is named as a co-defendant In the case styled as Charles M. Butler, III and Chole Butler v. Unified Life Ins. Co., et al. , Case No. 17-cv-00050-SPW-TJC, U.S. District Court for the District of Montana (Billings Div.) (“Butler case”), in which allegations of misrepresentation and claims handling were made against the independent insurance agency and a carrier, the plaintiff also named the Company as a party. The Company is asserting defenses against the claims not limited to that it doesn’t adjudicate claims and made no misrepresentations to Butler. While it is possible that a loss may arise from this case, the amount of such loss is not known or estimable at this time. In the case styled as Carter v. Companion Life Insurance Company et al ., Case No. 18-cv-350, U.S. District Court for the District of Alabama (“Carter case”), in which allegations of claims handling were made against the carrier and the plaintiff also named the Company as a party. The Carter case was received on March 20, 2018 and an Amended Complaint was subsequently filed on July 6, 2018. The Company has since moved to dismiss the Amended Complaint, and the parties are awaiting the Court’s ruling. While it is possible that a loss may arise from this case, the amount of such loss is not known or estimable at this time. The Company has also received claims from insureds relating to lack of carrier coverage, claims handling, and alleged deceptive sales practices relating to carriers with which we do business. In each of these individual insureds’ claims, the Company attempts to dismiss, challenge, or resolve the claims as quickly as possible. Other Purported Securities Class Action Lawsuits In September 2017, three putative securities class action lawsuits were filed against the Company and certain of its current and former executive officers. The cases were styled Cioe Investments Inc. v. Health Insurance Innovations, Inc., Gavin Southwell, and Michael Hershberger , Case No. 1:17-cv-05316-NG-ST, filed in the U.S. District Court for the Eastern District of New York on September 11, 2017; Michael Vigorito v. Health Insurance Innovations, Inc., Gavin Southwell, and Michael Hershberger , Case No. 1:17-cv-06962, filed in the U.S. District Court for the Southern District of New York on September 13, 2017; and Shilpi Kavra v. Health Insurance Innovations, Inc., Patrick McNamee, Gavin Southwell, and Michael Hershberger , Case No. 8:17-cv-02186-EAK-MAP, filed in the U.S. District Court for the Middle District of Florida on September 21, 2017. All three of the foregoing actions (the “Securities Actions”) were filed after a decline in the trading price of the Company’s common stock following the release of a report authored by a short-seller of the Company’s common stock raising questions about, among other things, the Company’s public disclosures relating to the Company’s regulatory examinations and regulatory compliance. All three of the Securities Actions, which were based substantially on the allegations raised in the short-seller report, contained substantially the same allegations, and alleged that the Company made materially false or misleading statements or omissions relating to regulatory c ompliance matters, particularly regarding the Company’s application for a third-party administrator license in the State of Florida. In November and December 2017, the Cioe Investments and Vigorito cases were transferred to the U.S. District Court for the Middle District of Florida, and on December 28, 2017, they were consolidated with the Kavra matter under the case caption, In re Health Insurance Innovations Securities Litigation , Case No. 8:17-cv-2186-EAK-MAP (M.D. Fla.). On February 6, 2018, the court appointed Robert Rector as lead plaintiff and appointed lead counsel, and lead plaintiff filed a consolidated complaint on March 23, 2018. The consolidated complaint, which dropped Patrick McNamee as a defendant and added Michael Kosloske as a defendant, largely sets forth the same factual allegations as the initially filed Securities Actions filed in September 2017 and adds allegations relating to alleged materially false statements and omissions relating to the regulatory proceeding previously initiated against the Company by the Montana State Auditor, Commissioner of Securities and Insurance (the “CSI”), which proceeding was dismissed on October 31, 2017 in light of CSI’s decision to join the Indiana Multistate Examination. The complaint also adds allegations regarding insider stock sales by Messrs. Kosloske and Hershberger. The consolidated complaint alleges violations of Section 10(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), SEC Rule 10b-5, and Section 20(a) of the Exchange Act. According to the consolidated complaint, the plaintiffs in the action are seeking an undetermined amount of damages, interest, attorneys’ fees and costs on behalf of putative classes of individuals and entities that acquired shares of the Company’s common stock on periods ending September 11, 2017. On May 7, 2018, the Company and the co-defendants filed a motion to dismiss call claims set forth in the complaint, and as of October 29, 2018, the motion had been fully briefed and is awaiting the court’s decision. At this time, the Company cannot predict the probable outcome of this action, and, accordingly, no amounts have been accrued in the Company’s condensed consolidated financial statements for this action. Putative Derivative Action Lawsuits Two individuals, Ian DiFalco and Dayle Daniels, filed separate but similar derivative action complaints on April 5 and April 6, 2018, respectively, in the Delaware Court of Chancery naming most of the Company’s directors and executive officers as defendants. The derivative complaints assert alleged violations of Section 14(a) of the Exchange Act, Section 10(b) of the Exchange Act and Rule 10b-5, and Section 20(a) of the Exchange Act, and claims for alleged breach of fiduciary duties, alleged unjust enrichment, alleged abuse of control, alleged gross mismanagement, and alleged waste of corporate assets. The factual allegations in the complaints are based largely on the factual allegations in the above-described consolidated securities class action consolidated complaint and include additional allegations relating to misconduct by third-party call centers utilized by the Company in its operations. The plaintiffs are seeking declaratory relief, direction to reform and improve corporate governance and internal procedures, and an undetermined amount of damages, restitution, interest, and attorneys’ fees and costs. On June 5, 2018, the court entered a stipulation and order staying the litigation pending resolution of the above-described securities litigation (In re Health Insurance Innovations Securities Litigation), whether by dismissal with prejudice or entry of final judgment. Defendants intend to vigorously defend against these claims. However, at this time, the Company cannot predict the probable outcome of these actions, and, accordingly, no amounts have been accrued in the Company’s condensed consolidated financial statements for this action. Telephone Consumer Protection Act The Company has received a number of private-party claims relating to advertising activities allegedly conducted by independently owned and operated licensed-agent distributors, who are only associated with the Company by their use of our technology and billing platform. Generally, these claims assert that the Company violated the Telephone Consumer Protection Act ("TCPA"), although we believe that the Company does not engage in such activities. In fact, the Company maintains internal and external compliance staff and processes to monitor distributor compliance. Historically, the Company has been successful at obtaining dismissals or settling the claims for immaterial amounts. In the previously reported case of Hicks, the Company was dismissed from the case with prejudice without any finding of liability and without it having to make settlement payment on its behalf. As part of the complete dismissal and resolution of the case in the Company’s favor, Hicks affirmatively stated that the Company made none of the alleged telephone calls as originally asserted in the complaint and had no liability or responsibility of the alleged marketing activities. The Company continues to defend itself through procedural motions in two other cases filed by what we have determined to be serial-professional plaintiffs known as Craig Cunningham and Kenneth Moser. In Cunningham, the Company has been successful at having the case dismissed twice, including receiving comments from the Federal Court encouraging Mr. Cunningham not to refile. Contrary to that suggestion, Mr. Cunningham refiled his case again and the Company has responded with another motion to dismiss. Moser, who like Cunningham, has been a plaintiff in hundreds of similar cases against companies nationwide. Similarly, the Company has received claims for alleged TCPA violations from other claimants, the majority of which are not lawsuits. The Company believes many of these individuals to be professional plaintiffs and not common consumers. The Company maintains an internal legal department that reviews these claims as they arise, coordinates the Company’s response to such, and supports outside counsel when litigation defense is required. While these types of claims have previously settled, been dismissed, or resolved without any material effect on the Company, there is a possibility in the future that one or more could have a material effect. The Company commonly uses outside legal counsel to defend against such claims and requires that the independently owned, licensed-agent distributors who are related to any such claims provide indemnification and reimbursement to the Company for the costs associated with these Claims. Other matters We enter into agreements in the ordinary course of business that may require us to indemnify the other party for claims brought by a third-party. From time to time, we have received requests for indemnification. Presently the Company is managing and responding to both formal demands and informal requests for indemnification from a number of carriers related to the MCE, states' investigations into carriers relating to agent licensing, and the TCPA claims identified above. Management cannot reasonably estimate any potential losses, but these claims could result in a material liability for us.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2018
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions There have been no material changes to the Related Party Transactions disclosures made in our Annual Report on Form 10-K for the period ended December 31, 2017, except for those noted in Note 6 and Note 10 above related to required payments under the TRA, exchanges under the Exchange Agreement, and the HPIH and HPI Operating Agreement.

Organization, Basis of Presen_2

Organization, Basis of Presentation and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Principles of Consolidation and Basis of Presentation	Principles of Consolidation and Basis of Presentation The accompanying condensed consolidated financial statements for the three and nine months ended September 30, 2018 and 2017 have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information. Accordingly, they do not include all of the financial information and footnotes required by GAAP for complete financial statements. The information included in this quarterly report, including the interim condensed consolidated financial statements and the accompanying notes, should be read in conjunction with the audited consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 . In the opinion of management, the accompanying condensed consolidated financial statements reflect all adjustments, which, except as disclosed in the below section titled "Reclassifications," include only normal recurring adjustments, necessary to state fairly the financial position, results of operations, stockholders' equity, and cash flows of the Company. The condensed consolidated results for th e three and nine months ended September 30, 2018 are not necessarily indicative of the results to be expected for any subsequent interim period or for the year ending December 31, 2018 . As an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), we benefit from certain temporary exemptions from various reporting requirements, including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We have also elected under the JOBS Act to delay the adoption of new and revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. As a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates. These exemptions will apply for a period of five years following the completion of our IPO on February 13, 2013. The Company will cease to be an emerging growth company as of December 31, 2018 .
Use of Estimates	Use of Estimates The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities at the date of the condensed consolidated financial statements. These estimates also affect the reported amounts of revenues and expenses during the reporting periods. Actual results could materially differ from those estimates.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In the following summary of recent accounting pronouncements, all references to effective dates of Financial Accounting Standards Board (“FASB”) guidance relate to nonpublic entities unless otherwise noted. As noted above, we have elected to delay the adoption of new and revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies under the provisions of the JOBS Act. Recently adopted accounting pronouncements In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, an update which requires companies to include amounts generally described as restricted cash and restricted cash equivalents in cash and cash equivalents when reconciling beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company has adopted this update during the first quarter of 2018 and has properly reported restricted cash and restricted cash equivalents in our beginning-of-period and end-of-period total cash and cash equivalents balance. Accounting pronouncements not yet adopted In July 2018, the FASB issued ASU No. 2018-10, Codification Improvements to Topic 842, Leases, to add clarity to certain areas within ASU 2016-02. The effective date and transition requirements will be the same as ASU 2016-02. The Company will evaluate and adopt this ASU in conjunction with ASU 2016-02. In May 2017, the FASB issued Accounting Standards Update (“ASU”) No. 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting, which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. The amendments are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted. We are currently evaluating the impact of adopting this standard, and will adopt this guidance on December 31, 2018, the date our emerging growth company status expires. We do not expect it to have a significant impact on our consolidated financial statements and disclosures. We will adopt this standard prospectively as required by the standard. In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment, which eliminates the requirement to calculate the implied fair value of goodwill (i.e., Step 2 of the goodwill impairment test) to measure a goodwill impairment charge. Instead, entities will record an impairment charge based on the excess of a reporting unit’s carrying amount over its fair value. This guidance will be effective for interim or annual goodwill impairment tests in fiscal years beginning after December 15, 2019 and will be applied prospectively. Early adoption is permitted for any impairment tests performed after January 1, 2017. The Company does not believe that this guidance will have a material impact on our consolidated financial statements. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, which provides amendments to the codification for eight specific cash flow issues such as the classification of debt prepayment or debt extinguishment costs to the classification of the proceeds from the settlement of insurance claims. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2018, and interim periods within fiscal years beginning after December 15, 2019. Early adoption is permitted, including adoption in an interim period. The Company will adopt this guidance on December 31, 2018, the date our emerging growth company status expires. The standard will be implemented using a retrospective transition method to each period presented, except where it is impracticable, and the amendments for those issues will be applied prospectively. We are currently evaluating the impact of this guidance on our consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which modifies lease accounting for lessees to increase transparency and comparability by requiring organizations to recognize lease assets and lease liabilities on the balance sheet and increasing disclosures about key leasing arrangements. The amendment updates the critical determinant from capital versus operating to whether a contract is or contains a lease because lessees are required to recognize lease assets and lease liabilities for all leases - financing and operating - other than short term. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. We will adopt this guidance in reporting periods beginning after December 15, 2018. The adoption of this standard will impact the Company’s consolidated balance sheet, but the Company is still assessing any other impacts this standard will have on its consolidated financial statements. The Company does not believe that the impact of adopting this standard will be material to the consolidated financial statements. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) which amends the existing revenue recognition standards. The standard is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, new and enhanced disclosures will be required. For most public entities, the standard became effective for annual and interim reporting periods beginning after December 15, 2017. For all other entities, the amendments in this update are effective for reporting periods beginning after December 15, 2018. As an emerging growth company, we are required to adopt this guidance on December 31, 2018, the date our emerging growth company status expires. We will apply the new standard using a modified retrospective approach with the cumulative effect of its application recognized at the date of initial application. We are implementing this new standard in close consultation with our Audit Committee. We have identified our various revenue streams that could be impacted by the new standard and have reviewed individual customer contracts related to these revenue streams to determine material differences between the current and new revenue standards. The new standard will impact the majority of our revenue streams. In accordance with ASU 2014-09, we will make estimates, including, but not limited to, the estimated revenue to be paid to us over the estimated life of the member policy. Our adoption of ASU 2014-09 will significantly change the timing of our revenue recognition over the course of the year, depending on when applications are approved. We have identified that we generally have two performance obligations, as defined in the standard, to our customers. These performance obligations typically include: 1. Sales and Enrollment 2. Bill, Collect, and Support Under current revenue recognition guidance, we generally recognize revenue ratably over the policy period as the members remit their payments. Under the new standard, the Sales and Enrollment performance obligation is considered complete once an application is approved. At the time of approval, we would record the entire amount of revenue allocated to the Sales and Enrollment performance obligation that the Company expects to receive over the life of the insurance policy or discount benefit plan. This estimate will be based on the expected persistency of the underlying insurance policy or discount benefit plan. The remaining performance obligations will be recognized ratably over the estimated life of the insurance policy or discount benefit plan. The Company has not concluded on the treatment of its cost to fulfill and obtain contracts under the new standard. We anticipate the adoption of the new standard will have a material impact to our opening balance sheet as of January 1, 2018 due to the cumulative effect of adopting the new standard. In addition, we believe our adoption of the new standard will have a material impact on our consolidated balance sheet and consolidated statement of income for the year ended December 31, 2018 however, a reasonable estimate of the quantitative impact of adopting this standard cannot be made at this time. To prepare for the additional disclosure requirements, we are currently implementing additional tools to support our revenue recognition and data collection processes, which will be in place and effective on December 31, 2018. The Company has reviewed all other issued, but not yet effective, accounting pronouncements and does not believe the future adoption of any such pronouncements may be expected to cause a material impact on our financial statements.

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2018
Payables and Accruals [Abstract]
Summary of Accounts Payable and Accrued Expenses	Accounts payable and accrued expenses consisted of the following as of ($ in thousands): September 30, 2018 December 31, 2017 Carriers and vendors payable $ 15,412 $ 14,726 Commissions payable 10,157 8,811 Accrued compensation and benefits 6,549 7,116 Accrued refunds 1,107 1,940 Accounts payable 323 3,725 Accrued professional fees 1,315 820 Accrued credit card/ACH fees 488 483 Other accrued expenses 2,390 2,104 Total accounts payable and accrued expenses $ 37,741 $ 39,725

Stock-based Compensation (Table

Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Weighted Average Assumptions	For stock appreciation rights ("SARs") granted or modified during the nine months ended September 30, 2018 and 2017 , the Black-Scholes option-pricing model was used with the following weighted average assumptions: Nine Months Ended September 30, 2018 2017 Risk-free rate 2.3 % 1.7 % Expected life 0.3 years 4.8 years Expected volatility 44.6 % 64.0 % Expected dividend none none
Summary of Restricted Shares, SARs, and Stock Options Granted	The following table summarizes restricted shares and SARs granted during the three and nine months ended September 30, 2018 and 2017 (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Restricted shares 50 — 63 855 SARs — 100 — 185
Summary of Stock-based Compensation Expenses	The following table summarizes stock-based compensation expense for the three and nine months ended September 30, 2018 and 2017 ($ in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Restricted shares $ 4,165 $ 2,246 $ 8,940 $ 3,306 SARs 268 434 1,996 1,116 Stock options — 3 — 15 Less amounts capitalized for internal-use software (89 ) — (433 ) — Total $ 4,344 $ 2,683 $ 10,503 $ 4,437
Summary of Unrecognized Stock-based Compensation	The following table summarizes unrecognized stock-based compensation expense and the remaining weighted average period over which such stock-based compensation expense is expected to be recognized as of September 30, 2018 ($ in thousands): Unrecognized Expense Weighted Average Remaining Years Restricted shares $ 9,062 1.8 SARs 1,234 1.9 Total $ 10,296

Net Income Per Share (Tables)

Net Income Per Share (Tables)	9 Months Ended
	Sep. 30, 2018
Earnings Per Share [Abstract]
Summary of Reconciliation of Numerators and Denominators of Basic and Diluted Net Income	The computations of basic and diluted net income per share attributable to HIIQ for the three and nine months ended September 30, 2018 and 2017 were as follows ($ in thousands, except share and per share data): Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Basic net income attributable to Health Insurance Innovations, Inc. $ 3,044 $ 3,885 $ 10,056 $ 14,102 Weighted average shares—basic 12,853,739 11,700,941 12,130,722 10,724,750 Effect of dilutive securities: Restricted shares 573,047 466,581 597,012 258,218 SARs 629,038 561,788 568,692 685,583 Stock options 4,629 13,642 6,385 24,204 Weighted average shares—diluted 14,060,453 12,742,952 13,302,811 11,692,755 Basic net income per share attributable to Health Insurance Innovations, Inc. $ 0.24 $ 0.33 $ 0.83 $ 1.31 Diluted net income per share attributable to Health Insurance Innovations, Inc. $ 0.22 $ 0.30 $ 0.76 $ 1.21
Summary of Securities Not Included in Calculation of Diluted Net Income	The following securities were not included in the calculation of diluted net income per share because such inclusion would be antidilutive (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Restricted Shares 50 — 50 405 SARs — 16 105 —

Organization, Basis of Presen_3

Organization, Basis of Presentation and Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Period of exemptions under JOBS Act	5 years
Cash and cash equivalents	$ 33,135		$ 40,907
Accounts receivable, net, prepaid expenses and other current assets	$ 2,661		2,227
Reclassification
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cash and cash equivalents			1,600
Accounts receivable, net, prepaid expenses and other current assets			$ (1,600)
Decrease in operating cash flows		$ 217

Long-term Advanced Commissions

Long-term Advanced Commissions (Details) - USD ($)	9 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Long term advanced commissions	$ 4,380,000	$ 0
Allowance for uncollectible accounts	$ 0

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 464	$ 479	$ 1,400	$ 1,500

Accounts Payable and Accrued _3

Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Payables and Accruals [Abstract]
Carriers and vendors payable	$ 15,412	$ 14,726
Commissions payable	10,157	8,811
Accrued compensation and benefits	6,549	7,116
Accrued refunds	1,107	1,940
Accounts payable	323	3,725
Accrued professional fees	1,315	820
Accrued credit card/ACH fees	488	483
Other accrued expenses	2,390	2,104
Total accounts payable and accrued expenses	$ 37,741	$ 39,725

Accounts Payable and Accrued _4

Accounts Payable and Accrued Expenses - Narrative (Details) $ in Millions	Sep. 30, 2018USD ($)
Payables and Accruals [Abstract]
Accrued wages related to severance	$ 3.3

Debt (Details)

Debt (Details) - Credit Agreement - Revolving Credit Facility	Sep. 30, 2018USD ($)
Line of Credit Facility [Line Items]
Outstanding balance	$ 0
Revolving line of credit	$ 30,000,000

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)	Jun. 07, 2018	Jun. 06, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Oct. 13, 2017
Class of Stock [Line Items]
Number of shares transferred to treasury (in shares)			45,400	10,300	83,700	21,900
Cash paid to cover tax obligations for settlement of vested restricted stock			$ 2,200,000	$ 263,000	$ 3,470,000	$ 448,000
Treasury Stock
Class of Stock [Line Items]
Number of shares transferred to treasury (in shares)					(83,709)		(39,049)
Repurchase of common stock (in shares)					(426,135)		(222,184)
Treasury Stock | Forfeitures of Restricted Stock Awards
Class of Stock [Line Items]
Number of shares acquired during the period (in shares)			0	0	0	0
Class A Common Stock
Class of Stock [Line Items]
Authorized amount of share repurchase program								$ 50,000,000
Repurchase of common stock (in shares)			310,890	0	426,135	0	222,184
Repurchase of common stock, average price per share (in USD per share)			$ 50.50		$ 45.77		$ 22.15
Share price (in USD per share)	$ 31.01
Health Plan Intermediaries, LLC | Class A Common Stock
Class of Stock [Line Items]
Sale of stock (in shares)	1,287,000
Health Plan Intermediaries, LLC | Class B Common Stock
Class of Stock [Line Items]
Exchange of stock (in shares)		1,287,000
Health Plan Intermediaries, LLC | Membership Interests
Class of Stock [Line Items]
Exchange of stock (in shares)		1,287,000
Health Plan Intermediaries Sub, LLC | Class A Common Stock
Class of Stock [Line Items]
Sale of stock (in shares)	13,000
Health Plan Intermediaries Sub, LLC | Class B Common Stock
Class of Stock [Line Items]
Exchange of stock (in shares)		13,000
Health Plan Intermediaries Sub, LLC | Membership Interests
Class of Stock [Line Items]
Exchange of stock (in shares)		13,000
Health Plan Intermediaries Sub, LLC | Class A Common Stock
Class of Stock [Line Items]
Issuance of common stock (in shares)		13,000
Health Plan Intermediaries, LLC | Class A Common Stock
Class of Stock [Line Items]
Issuance of common stock (in shares)		1,287,000

Stock-based Compensation - Summ

Stock-based Compensation - Summary of Weighted Average Assumptions (Details) - SARs	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free rate	2.30%	1.70%
Expected life	120 days	4 years 9 months 18 days
Expected volatility	44.60%	64.00%
Expected dividend	0.00%	0.00%

Stock-based Compensation - Su_2

Stock-based Compensation - Summary of Restricted Shares, SARs, and Stock Options (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Restricted shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted during the period (in shares)	50	0	63	855
SARs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
SARs and options granted during the period (in shares)	0	100	0	185

Stock-based Compensation - Su_3

Stock-based Compensation - Summary of Stock-based Compensation Expenses (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Less amounts capitalized for internal-use software	$ (89,000)	$ 0	$ (433,000)	$ 0
Total	4,344,000	2,683,000	10,503,000	4,437,000
Restricted shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	4,165,000	2,246,000	8,940,000	3,306,000
SARs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	268,000	434,000	1,996,000	1,116,000
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 0	$ 3,000	$ 0	$ 15,000

Stock-based Compensation - Su_4

Stock-based Compensation - Summary of Unrecognized Stock-based Compensation (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2018USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized Expense	$ 10,296
Restricted shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized Expense	$ 9,062
Weighted Average Remaining Years	1 year 9 months 30 days
SARs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized Expense	$ 1,234
Weighted Average Remaining Years	1 year 10 months 28 days

Stock-based Compensation - Narr

Stock-based Compensation - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares exercised (in shares)	2,500	10,700	5,800	29,500
Shares forfeited (in shares)	0	0	0	0
Income tax benefits from stock-based activity	$ 402,000	$ 380,000	$ 760,000	$ 4,000,000
Capitalized stock-based compensation	$ 89,000	$ 0	$ 433,000	$ 0
Class A Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares exercised (in shares)	111,200	89,800	125,900	1,000,000
SARs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares exercised (in shares)	143,100	110,500	163,000	1,400,000
Shares forfeited (in shares)	7,500	17,500	7,500	17,500
Performance restricted shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance shares issued for restricted shares (in shares)	0	0	179,400	0
Restricted shares forfeited (in shares)	35,000	0	35,000	0

Net Income per Share - Summary

Net Income per Share - Summary of Reconciliation of Numerators and Denominators of Basic and Diluted Net Income (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Basic securities
Basic net income attributable to Health Insurance Innovations, Inc.	$ 3,044	$ 3,885	$ 10,056	$ 14,102
Weighted average shares—basic (in shares)	12,853,739	11,700,941	12,130,722	10,724,750
Effect of dilutive securities:
Weighted average shares—diluted (in shares)	14,060,453	12,742,952	13,302,811	11,692,755
Basic net income per share attributable to Health Insurance Innovations, Inc. (in USD per share)	$ 0.24	$ 0.33	$ 0.83	$ 1.31
Diluted net income per share attributable to Health Insurance Innovations, Inc. (in USD per share)	$ 0.22	$ 0.30	$ 0.76	$ 1.21
Restricted shares
Effect of dilutive securities:
Dilutive securities (in shares)	573,047	466,581	597,012	258,218
SARs
Effect of dilutive securities:
Dilutive securities (in shares)	629,038	561,788	568,692	685,583
Stock options
Effect of dilutive securities:
Dilutive securities (in shares)	4,629	13,642	6,385	24,204

Net Income Per Share Net Income

Net Income Per Share Net Income per Share - Summary of Securities Not Included in Calculation of Diluted Net Income (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)			2,541,667	3,841,667
Restricted shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	50,000	0	50,000	405,000
SARs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	0	16,000	105,000	0

Net Income Per Share - Narrativ

Net Income Per Share - Narrative (Details) - shares	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Earnings Per Share [Abstract]
Anti-dilutive securities (in shares)	2,541,667	3,841,667

Income Taxes (Details)

Income Taxes (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Income Taxes [Line Items]
Effective tax rate	26.90%	32.50%	25.40%	16.40%
Provision for income taxes	$ 1,466,000	$ 2,889,000	$ 4,757,000	$ 4,220,000
Unrecognized tax benefits	$ 0	$ 0	$ 0	$ 0
HII
Income Taxes [Line Items]
Effective tax rate	15.50%	29.10%	19.30%	15.00%
HP
Income Taxes [Line Items]
Effective tax rate	0.00%	3.70%	0.00%	3.70%

Commitments and Contingencies (

Commitments and Contingencies (Details)	Apr. 06, 2018plaintiff	Feb. 13, 2013	Sep. 30, 2018USD ($)casestateshares	Sep. 30, 2017USD ($)lawsuit	Dec. 31, 2017USD ($)
Other Commitments [Line Items]
Cash distributions			$ 2,182,000		$ 3,353,000
TRA liability, current			1,137,000		1,775,000
TRA liability, non-current			$ 26,293,000		15,096,000
Number of states involved in multistate market conduct examination | state			43
Health Plan Intermediaries, LLC
Other Commitments [Line Items]
Cash distributions			$ 2,800,000	$ 5,300,000
Deferred tax liabilities			0		$ 638,000
Tax Receivable Agreement
Other Commitments [Line Items]
Payments under tax receivable agreement			1,200,000
Tax Receivable Agreement | Tax Receivable Agreement
Other Commitments [Line Items]
TRA liability			27,400,000
TRA liability, current			1,100,000
TRA liability, non-current			$ 26,300,000
Class A Common Stock | Common Stock Issuance Over Allotment Option | Underwriters Over Allotment Option
Other Commitments [Line Items]
Issuance of common stock (in shares) | shares			6,125,000
Pending Litigation | Purported Securities Class Action Lawsuits
Other Commitments [Line Items]
Number of pending lawsuits | lawsuit				3
Amount accrued			$ 0
Pending Litigation | Putative Derivative Action Lawsuits
Other Commitments [Line Items]
Amount accrued			$ 0
Number of plaintiffs | plaintiff	2
Pending Litigation | Craig Cunningham, Kenneth Moser, and Amanda Hicks V. Company
Other Commitments [Line Items]
Number of pending lawsuits | case			2
Series B Membership Interests
Other Commitments [Line Items]
Percent of required tax savings payout		85.00%
Percent of tax saving the company will benefit		15.00%